Eurizon Capital SGR S.p.A. Invests $2.43 Million in Insmed, Inc. $INSM

Eurizon Capital SGR S.p.A. bought a new position in Insmed, Inc. (NASDAQ:INSM) in the 4th quarter, HoldingsChannel reports. The fund bought 13,969 shares of the biopharmaceutical company’s stock, valued at approximately $2,431,000.

Several other hedge funds and other institutional investors have also modified their holdings of INSM. Vanguard Group Inc. boosted its position in shares of Insmed by 13.0% in the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after buying an additional 2,291,328 shares during the period. Artisan Partners Limited Partnership boosted its position in shares of Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after buying an additional 1,623,342 shares during the period. Orbis Allan Gray Ltd acquired a new stake in shares of Insmed in the second quarter worth $153,389,000. Darwin Global Management Ltd. boosted its position in shares of Insmed by 5.8% in the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock worth $2,897,797,000 after buying an additional 1,112,824 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Insmed by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock worth $751,936,000 after buying an additional 539,625 shares during the period.

Insider Buying and Selling at Insmed

In other Insmed news, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $143.52, for a total value of $1,535,520.48. Following the transaction, the chief executive officer owned 301,185 shares in the company, valued at approximately $43,226,071.20. This trade represents a 3.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 156,643 shares of company stock worth $24,513,766 over the last three months. Corporate insiders own 2.10% of the company’s stock.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $103.73 on Wednesday. Insmed, Inc. has a 1 year low of $70.57 and a 1 year high of $212.75. The business has a fifty day simple moving average of $133.66 and a 200 day simple moving average of $157.25. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The firm has a market cap of $22.48 billion, a price-to-earnings ratio of -18.04 and a beta of 0.79.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. During the same period last year, the company earned ($1.42) earnings per share. The business’s revenue was up 229.7% compared to the same quarter last year. As a group, sell-side analysts predict that Insmed, Inc. will post -2.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

INSM has been the subject of several recent analyst reports. Stifel Nicolaus raised their target price on Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Insmed in a report on Friday, May 8th. Jefferies Financial Group initiated coverage on Insmed in a report on Monday, March 16th. They set a “buy” rating and a $228.00 price objective for the company. Finally, Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $166.00 to $212.00 in a report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $210.95.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.